Drug – bio-affecting and body treating compositions – Lymphokine – Interleukin
Reexamination Certificate
2010-08-26
2011-10-04
Saoud, Christine J (Department: 1647)
Drug, bio-affecting and body treating compositions
Lymphokine
Interleukin
C514S001100, C514S001700, C514S021200, C530S350000, C530S351000
Reexamination Certificate
active
08029775
ABSTRACT:
Use of IL-31 agonists, including IL-31, are used to treat agonists are used to treat asthma, airway hyper-responsiveness or allergic rhinitis. The method comprise inhibiting, reducing, limiting or minimizing production of proinflammatory cytokines and include administration of the IL-31 agonist during sensitization or challenge resulting in the asthma, airway hyper-responsiveness or allergic rhinitis state.
REFERENCES:
patent: 5925735 (1999-07-01), Baumgartner et al.
patent: 7064186 (2006-06-01), Sprecher et al.
patent: 7425325 (2008-09-01), Sprecher et al.
patent: 7459293 (2008-12-01), Sprecher et al.
patent: 7494804 (2009-02-01), Sprecher et al.
patent: 7507795 (2009-03-01), Sprecher et al.
patent: 7514077 (2009-04-01), Yao et al.
patent: 7531636 (2009-05-01), Sprecher et al.
patent: 7531637 (2009-05-01), Siadak et al.
patent: 7723048 (2010-05-01), Bilsborough et al.
patent: 7740834 (2010-06-01), Sprecher et al.
patent: 2006/0182743 (2006-08-01), Bilsborough
patent: 2006/0188499 (2006-08-01), Leung et al.
patent: 2006/0188500 (2006-08-01), Leung et al.
patent: 2006/0228329 (2006-10-01), Brady et al.
patent: 2008/0260686 (2008-10-01), Bilsborough et al.
patent: 2009/0149635 (2009-06-01), Sprecher et al.
patent: 2009/0252732 (2009-10-01), Siadak et al.
patent: 03/060090 (2003-07-01), None
patent: 2004/003140 (2004-01-01), None
patent: 2006/081573 (2006-08-01), None
patent: 2006/122079 (2006-11-01), None
patent: 2008/028192 (2008-03-01), None
Riken, 1999, (GenBank Acc. No. AV040649).
Riken, 1999, (GenBank Acc. No. AV044404).
Riken, 1999, (GenBank Acc. No. AV268991).
Riken, 1999, (GenBank Acc. No. AV280874).
National Cancer Institute, 1997, (GenBank Acc. No. BF152807).
Riken, 2001, (GenBank Acc. No. BB610257).
Riken, Accession No. AK005939, 1999.
Riken, Accession No. AK005939, Jul. 5, 2001.
National Institutes of Health, 1999, (GenBank Acc. No. CA464033).
Riken, 2002, (GenBank Acc. No. BY706076).
Washington University School of Medicine, 2002, (GenBank Acc. No. CF105870).
RZPD Deutsches Ressourcenzentrum fuer Genomforschung GmbH, 2003, (GenBank Acc. No. BX639332).
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 3482986, Jan. 11, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 16727183, Feb. 24, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10456006, Mar. 14, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 8480322, Jan. 13, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 49775248, Oct. 5, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 10005090, Mar. 10, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 20965871, Mar. 16, 2001.
Whitehead Institute for Biomedical Research, Mouse Public Genomic Sequence TDB 44835892, Sep. 20. 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 50734527, Oct. 6, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 40505897, Aug. 31, 2001.
Sanger Center, Mouse Public Genomic Sequence TDB 1021719, Jan. 4, 2001.
Washington University Genome Sequencing Center, Mouse Public Genomic Sequence TDB 22973884, Apr. 16, 2001.
Abstract from the American Society of Human Genetics Meeting, Nov. 7, 2003 on Gene Structure and Function.
EMBL Accession No. AC048338, Apr. 2000.
EMBL Accession No. AA381907, Apr. 1997.
Dillon et al., “Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice,” Nature Immunology 5(7):752-760, Jul. 2004.
Bilsborough et al., “IL-31 is associated with cutaneous lymphocyte antigen-positive skin homing T-cells in patients with atopic dermatitis”, Journal of Allergy and Clinical Immunology, Mosby—Yearly Book, Inc., US 117(2): 418-425, Feb. 7, 2006.
Sonkoly et al., “IL-31: A new link between t-cells and pruritus in atopic skin inflammation”, Journal of Allergy and Clinical Immunology, Mosby—Yearly Book, Inc., US 117(2): 411-417, Feb. 2006.
Takaoka et al., “Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis”, Experimental Dermatology, 15 (3): 161-167, Mar. 2006.
Takaoka et al., “Expression of IL-31 gene transcript in NC/Nga mice with atopic dermatitis”, European Journal of Pharmacology, Amsterdam, NL, 516 (2): 180-181, May 31, 2005.
Goding, Journal of Immunological Methods vol. 39: 285-308, 1980.
Ständer et al., Hautarzt 54: 413-417, 2003.
Claudy, Pathologie et Biologie, L'Expansion Scientifique Francaise, Paris, FR 44(10): 888-894, 1996.
Leung et al., “New insights into atopic dermititis”, Journal of Clinical Investigation 113(5): 651-657, Mar. 2004.
Boguniewics et al., “Atopic dermititis”, J Allergy Clin Immunol, 117(2): S475-S480, Feb. 2006.
Castellani et al., “Interleukin-31: A new cytokine involved in inflammation of the skin”, International Journal of Immunopathology and Pharmacology, 19(1): 1-4, Jan. 13, 2006.
“Monoclonal Anti-human IL-31 Antibody”, R&D Systems, Inc., Apr. 18, 2006.
Presta et al., “Engineering of therapeutic antibodies to minimize immunogenicity and optimize function,” Advanced Drug Delivery Reviews 58(5-6): 640-656, 2006.
Conti et al., “Modulation of autoimmunity by the latest interleukins (with special emphasis on IL-32)” Autoimmunity Reviews 6(3): 131-137, 2007.
EMBL Accession No. AK005939, Feb. 8, 2001.
Neis et al., “Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis,” Journal of Allergy and Clinical Immunology, 118(4): 930-937, Oct. 1, 2006.
Wills-Karp, M., “The gene encoding inerleukin-13: a susceptibility locus for asthma and related traits,” Respiratory Research, 1(1): 19-23, Jul. 17, 2000.
Dillon et al., “Transgenic mice overexpressing a novel cytokine (IL-31) develop a severe pruritic skin phenotype resembling atopic dermatitis,” European Cytokine Network 14(3): 81, 2003.
Perrigoue et al., “IL-31-IL-31R interactions negatively regulate type 2 inflammation in the lung,” Journal of Experimental Medicine 204(3): 481-487, Mar. 19, 2007.
Jawa et al., “Expression, regulation and signaling by interleukin 31 receptor alpha (IL-31RA) in bronchnopulmonary epithelial cells and pulmonary macrophages,” Assocation for Academic Surgery and Society of University Surgeons, abstract, (2007).
Brusasco and Pellegrino, “Airway Hyperresponsiveness: From Molecules to Bedside,” J. Appl. Physiol. 95: 1305-1313, 2003.
Bilsborough Janine M.
Chadwick Eric M.
Mudri Sherri L.
Adams Robyn
Lockard Jon M
Saoud Christine J
Walsh Brian J.
ZymoGenetics Inc.
LandOfFree
Methods of determining dose of IL-31 agonist to treat... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of determining dose of IL-31 agonist to treat..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of determining dose of IL-31 agonist to treat... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4278017